Chidamide tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Brand
- Epidaza
- Company
- Shenzhen Chipscreen Biosciences
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- (1) Relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one previous course of systemic chemotherapy. (2) With an aromatase inhibitor for postmenopausal patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer that has relapsed or progressed after endocrine therapy. (3) With R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for previously untreated diffuse large B-cell lymphoma (DLBCL) expressing both MYC and BCL2. The label identifies the PTCL and DLBCL indications as conditionally approved.
- Indication source and scope
- 2024-04-24
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to: (1) relapsed or refractory PTCL after at least one previous course of systemic chemotherapy; (2) use with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for previously untreated DLBCL expressing both MYC and BCL2.
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.chipscreen.com/products/525.html
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.chipscreen.com/media/upload/%E8%A5%BF%E8%BE%BE%E6%9C%AC%E8%83%BA%E7%89%87%E8%AF%B4%E6%98%8E%E4%B9%A6%2020240424.pdf
Open the interactive record, public price references and discussions